Animal Models of Human Pathology: Revision, Relevance and Refinements (3rd Edition)

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 31 March 2025 | Viewed by 6960

Special Issue Editor


E-Mail Website
Guest Editor
Institute of Pathology, Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Interests: challenges in animal model research; translation; unbiased reporting of animal model characteristics and results; ethical justification
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

The use of animal models of human pathology is accepted on the assumption that it benefits humans. However, recent publications have shown that research on animals faces serious challenges. The increasing number of potential targets, molecular pathways or treatment strategies, which have been recognized as promising in animal models, have failed when translated into human trials. We have reached the point where the clinical relevance of animal models needs urgent clarification.

Multiple methodological problems in animal research have already been exposed, such as poor experimental design, inadequate use of fundamental statistical principles (i.e., randomization, blinding, inadequate power, inadequate sample size, pseudo-replication, etc.) and nontransparent reporting, which results in low scientific validity and irreproducibility of results. However, research on animal models also requires comprehensive knowledge about the model, as well as an understanding of the complex pathogenesis of diseases, which involves both local and systemic effects in the body. Every animal model has its own characteristics, advantages and limitations. There are factors specific to the disease or animal model that can influence not only the severity of the disease but also underlying mechanisms, and, when these factors are not taken into account, research may result in the discovery of new targets and disease pathways that are of no scientific or clinical value. There are also animal-model-specific factors that can seriously affect the results and lead to false conclusions and failed translation. Although the overall animal health and welfare issues—such as animal clinical state, morbidity, mortality, humane endpoints and humane interventions, whole body necropsy findings, sampling principles and pathohistological diagnosis—are of vital importance in the interpretation of the molecular mechanisms or treatment strategies in an organism, this information is usually lacking or rarely properly addressed in animal model studies.

The purpose of this Special Issue is thus to promote the submissions of high-quality papers of basic research using animal models to understand diseases and underlying mechanisms or to investigate new treatment strategies in various human diseases such as cancer, bowel diseases, kidney injury, Parkinson’s disease, etc. New approaches towards the use of animal models or refinements of particular animal models of human pathology as well as methodological and welfare principles (such as experimental design and welfare or supportive measures in animal models) are also welcome.

Dr. Martina Perše
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • animal models
  • biomarkers
  • human disease
  • pathology
  • translation
  • mechanisms
  • nephrology
  • gastroenterology
  • urology
  • neuroscience
  • cancer
  • experimental design
  • reproducibility
  • refinements

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Related Special Issues

Published Papers (5 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

6 pages, 206 KiB  
Editorial
Animal Models of Human Pathology: Revision, Relevance and Refinements
by Martina Perše
Biomedicines 2024, 12(11), 2418; https://doi.org/10.3390/biomedicines12112418 - 22 Oct 2024
Viewed by 1049
Abstract
Animal Models of Human Pathology [...] Full article

Research

Jump to: Editorial, Review

13 pages, 2016 KiB  
Article
Analysis of Intervertebral Disc Degeneration Induced by Endplate Drilling or Needle Puncture in Complement C6-Sufficient and C6-Deficient Rabbits
by Amelie Kuhn, Markus Huber-Lang, Sebastian Weckbach, Jana Riegger, Graciosa Q. Teixeira, Volker Rasche, Jörg Fiedler, Cornelia Neidlinger-Wilke and Rolf E. Brenner
Biomedicines 2024, 12(8), 1692; https://doi.org/10.3390/biomedicines12081692 - 30 Jul 2024
Viewed by 595
Abstract
Previous studies indicate an implication of the terminal complement complex (TCC) in disc degeneration (DD). To investigate the functional role of TCC in trauma-induced DD in vivo, the model of endplate (EP) drilling was first applied in rabbits using a C6-deficient rabbit strain [...] Read more.
Previous studies indicate an implication of the terminal complement complex (TCC) in disc degeneration (DD). To investigate the functional role of TCC in trauma-induced DD in vivo, the model of endplate (EP) drilling was first applied in rabbits using a C6-deficient rabbit strain in which no TCC formation was possible. In parallel the model of needle puncture was investigated. Using a minimally invasive surgical intervention, lumbar rabbit intervertebral discs (IVDs) were treated with EP drilling or needle puncture. Degenerative effects of both surgical interventions were assessed by Pfirrmann grading and T2 quantification of the IVDs based on high-resolution MRI (11.7 T), as well as radiographic determination of disc height index. Pfirrmann grading indicated significant degenerative effects after EP drilling. Contrary to our assumption, no evidence was found that the absence of TCC formation in C6-deficient rabbits reduces the development of DD compared to C6-sufficient animals. EP drilling was proven to be suitable for application in rabbits. However, results of the present study do not provide clear evidence of a central functional role of TCC within DD and suggest that TCC deposition in DD patients may be primarily considered as a marker of complement activation during DD progression. Full article
Show Figures

Figure 1

19 pages, 3954 KiB  
Article
Evidence-Based Severity Assessment of Animal Models for Pancreatic Cancer
by Tim Schreiber, Ingo Koopmann, Jakob Brandstetter, Steven R. Talbot, Lea Goldstein, Lisa Hoffmann, Anna Schildt, Markus Joksch, Bernd Krause, Robert Jaster, Rupert Palme, Dietmar Zechner, Brigitte Vollmar and Simone Kumstel
Biomedicines 2024, 12(7), 1494; https://doi.org/10.3390/biomedicines12071494 - 5 Jul 2024
Viewed by 1140
Abstract
Animal models are crucial to preclinical oncological research and drug development. Animal experiments must be performed in accordance with the 3R principles of replacement and reduction, if possible, and refinement where these procedures remain crucial. In addition, European Union legislations demand a continuous [...] Read more.
Animal models are crucial to preclinical oncological research and drug development. Animal experiments must be performed in accordance with the 3R principles of replacement and reduction, if possible, and refinement where these procedures remain crucial. In addition, European Union legislations demand a continuous refinement approach, as well as pro- and retrospective severity assessment. In this study, an objective databased severity assessment was performed in murine models for pancreatic cancer induced by orthotopic, subcutaneous, or intravenous injection of Panc02 cells. Parameters such as body weight change, distress score, perianal temperature, mouse grimace scale, burrowing, nesting behavior, and the concentration of corticosterone in plasma and its metabolites in feces were monitored during tumor progression. The most important parameters were combined into a score and mapped against a reference data set by the Relative Severity Assessment procedure (RELSA) to obtain the maximum achieved severity for each animal (RELSAmax). This scoring revealed a significantly higher RELSAmax for the orthotopic model than for the subcutaneous and intravenous models. However, compared to animal models such as pancreatitis and bile duct ligation, the pancreatic cancer models are shown to be less severe. Data-based animal welfare assessment proved to be a valuable tool for comparing the severity of differently induced cancer models. Full article
Show Figures

Figure 1

Review

Jump to: Editorial, Research

27 pages, 1416 KiB  
Review
Primary Bone Tumors and Breast Cancer-Induced Bone Metastases: In Vivo Animal Models and New Alternative Approaches
by Argia Ucci, Luca Giacchi and Nadia Rucci
Biomedicines 2024, 12(11), 2451; https://doi.org/10.3390/biomedicines12112451 - 25 Oct 2024
Viewed by 1156
Abstract
Bone is the preferential site of metastasis for the most common tumors, including breast cancer. On the other hand, osteosarcoma is the primary bone cancer that most commonly occurs and causes bone cancer-related deaths in children. Several treatment strategies have been developed so [...] Read more.
Bone is the preferential site of metastasis for the most common tumors, including breast cancer. On the other hand, osteosarcoma is the primary bone cancer that most commonly occurs and causes bone cancer-related deaths in children. Several treatment strategies have been developed so far, with little or no efficacy for patient survival and with the development of side effects. Therefore, there is an urgent need to develop more effective therapies for bone primary tumors and bone metastatic disease. This almost necessarily requires the use of in vivo animal models that better mimic human pathology and at the same time follow the ethical principles for the humane use of animal testing. In this review we aim to illustrate the main and more suitable in vivo strategies employed to model bone metastases and osteosarcoma. We will also take a look at the recent technologies implemented for a partial replacement of animal testing. Full article
Show Figures

Figure 1

31 pages, 4261 KiB  
Review
Preclinical Models of Hepatocellular Carcinoma: Current Utility, Limitations, and Challenges
by Antonio Cigliano, Weiting Liao, Giovanni A. Deiana, Davide Rizzo, Xin Chen and Diego F. Calvisi
Biomedicines 2024, 12(7), 1624; https://doi.org/10.3390/biomedicines12071624 - 22 Jul 2024
Cited by 1 | Viewed by 2111
Abstract
Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years. In addition to the traditional chemically and dietary-induced HCC models, a broad spectrum of novel preclinical tools have been [...] Read more.
Hepatocellular carcinoma (HCC), the predominant primary liver tumor, remains one of the most lethal cancers worldwide, despite the advances in therapy in recent years. In addition to the traditional chemically and dietary-induced HCC models, a broad spectrum of novel preclinical tools have been generated following the advent of transgenic, transposon, organoid, and in silico technologies to overcome this gloomy scenario. These models have become rapidly robust preclinical instruments to unravel the molecular pathogenesis of liver cancer and establish new therapeutic approaches against this deadly disease. The present review article aims to summarize and discuss the commonly used preclinical models for HCC, evaluating their strengths and weaknesses. Full article
Show Figures

Figure 1

Back to TopTop